▌Top Stocks · HEALTHCARE DIVIDEND·Updated November 18, 2026
Top Healthcare Dividend Stocks: Our 5 Picks for November 2026
Healthcare dividend stocks span insurers, distributors, diagnostics, medical devices, and branded medicines in this five-stock November 2026 countdown.
Top Stocks · HEALTHCARE DIVIDENDUpdated November 18, 2026
Healthcare dividend stocks remain attractive because the sector serves needs that do not disappear when economic growth slows. Patients still require medicines, diagnostics, procedures, insurance coverage, and pharmacy services, giving established operators exposure to recurring demand. For income-focused investors, that defensive profile can be especially valuable when market leadership is narrow or uncertainty is elevated. The strongest candidates also pair shareholder distributions with businesses that can reinvest in products, expand installed bases, or deepen relationships with providers and patients.
The healthcare value chain offers several ways to pursue that combination. Upstream companies develop branded medicines, devices, diagnostics, and nutritional products; distributors and pharmacy platforms sit between manufacturers, providers, and patients; and managed-care businesses coordinate insurance and pharmacy-benefit services. Durable reimbursement, switching costs, clinical expertise, and broad installed bases can all support resilience. Abbott has highlighted growth in medical devices and diagnostics and increased its quarterly dividend in December 2025, while Medtronic raised its quarterly dividend in 2026 and continues to emphasize product development and tuck-in acquisitions.
This countdown covers five US-listed healthcare businesses across those sub-segments, from pharmacy and benefits management to medical technology, diagnostics, pharmaceuticals, and MedTech. The ordering starts with rank #5 and moves toward the best pick at #1. Each company is assessed for how directly and deeply it participates in the healthcare dividend theme, followed by the quality of its earnings, margins, growth profile, valuation, and recent operating momentum.
Our screen focused on US-listed healthcare companies with market capitalizations above $500 million and meaningful exposure to products or services that can support recurring healthcare demand. We ranked candidates first by depth of exposure to the healthcare dividend theme, then by business fundamentals, including profitability, growth, valuation, balance-sheet considerations, and earnings execution. Composite quality grades and analyst consensus provide additional context, but they do not replace company-specific risk analysis. The list is presented in countdown order: the best pick is reserved for #1 at the end.
What they do. The company combines health insurance, pharmacy-benefit management, specialty and mail-order pharmacy, retail pharmacy, and consumer-health operations. Its Health Care Benefits segment serves employer, government, individual, Medicare, Medicaid, and prescription-drug-plan customers, while Health Services manages formularies, pharmacy networks, clinical programs, and medical spending. That breadth gives CVS an integrated position across payer, pharmacy, and benefits administration rather than a single-product healthcare exposure.
Why it fits.CVS is one of the clearest service-platform matches for this theme. Insurance premiums, prescription fulfillment, pharmacy-benefit administration, specialty pharmacy, and ancillary services all connect the company to recurring healthcare activity. The combination of Aetna-related benefits operations, pharmacy networks, mail order, and retail locations also creates multiple revenue streams inside healthcare, satisfying the theme more directly than a diversified company with only a small healthcare division.
Numbers that matter. Revenue growth was 5.4% year over year, while earnings growth was 188.8% and next-year EPS is estimated at 8.6964. The valuation is comparatively restrained, with a trailing P/E of 10.2892 and forward P/E of 10.5597. Profitability is thinner than at the device and pharmaceutical leaders in this group: gross margin is 13.7%, operating margin is 3.06%, and net margin is 2.64%, although ROE is 14.36% and ROA is 3.11%.
Recent momentum.CVS reported $2.09 of EPS against a $1.62 estimate on November 4, 2026, a 29.0% surprise. It has beaten estimates in all eight quarters shown, and the analyst panel includes seven Buy ratings and three Hold ratings, with no Sell count provided. The consensus score is 4.5357 and the average target is $109.3062, offering evidence of constructive sentiment despite the company’s relatively low-margin operating model.
What they do. The company develops and sells medical supplies, devices, laboratory equipment, diagnostics, drug-delivery systems, vascular-access products, infusion technologies, and surgical products worldwide. Its Medical Essentials, Connected Care, BioPharma Systems, Interventional, and Life Sciences activities serve hospitals, clinicians, laboratories, pharmaceutical companies, and researchers. This portfolio places BDX deep inside institutional workflows, where products such as catheters, syringes, specimen-collection systems, medication-management tools, and diagnostics can become embedded in routine care.
Why it fits.BDX is a focused medical-technology and supplies play, giving it direct exposure to the upstream product-maker portion of the healthcare value chain. Its broad range of consumables, laboratory systems, medication-safety products, and procedure-related equipment supports the type of installed-base and switching-cost advantages that can make healthcare cash flows defensive. It also brings diagnostics and life-science tools into a dividend-oriented portfolio rather than relying exclusively on pharmaceutical sales.
Numbers that matter. Revenue declined 10.5% year over year, but earnings growth was 47.6% and next-year EPS is estimated at 13.3017. The core valuation data show a trailing P/E of 42.7806 and forward P/E of 16.3934, suggesting that the earnings outlook materially affects how the stock is valued. Gross margin is 47.0%, operating margin is 15.67%, and net margin is 5.89%; ROE is 5.66% and ROA is 3.59%.
Recent momentum.BDX delivered $4.15 of EPS versus a $4.06 estimate on November 5, 2026, a 2.2% surprise. The company has beaten estimates in all eight quarters shown, although the magnitude of those beats has generally been modest. Analyst opinion is more measured than for CVS: one Buy, six Holds, and one Sell produce a consensus score of 4, alongside an average target of $226.1429. That mix points to dependable execution but also continuing questions around growth and valuation.
What they do. The company operates across Established Pharmaceutical Products, Diagnostics, Nutritional Products, and Medical Devices. Its offerings include laboratory and point-of-care testing systems, molecular diagnostics, infant and adult nutrition, generic medicines, cardiovascular devices, diabetes-care products, and neuromodulation technologies. That mix gives Abbott exposure to both recurring consumables and higher-value equipment, while its international healthcare footprint broadens the revenue base beyond one product category.
Why it fits. Abbott offers one of the most balanced upstream healthcare profiles in the group. Diagnostics and medical devices connect it to installed equipment, testing demand, and clinical workflows, while nutrition and established pharmaceuticals add additional healthcare revenue streams. The theme context also identifies Abbott’s medical-device and diagnostics growth and notes that it increased its quarterly dividend in December 2025, making the company’s product breadth particularly relevant to dividend investors.
Numbers that matter. Revenue growth was 14.5% year over year, but earnings growth declined 43.6%; next-year EPS is estimated at 5.937. Abbott’s trailing P/E is 40.0933 and forward P/E is 18.315, reflecting a substantial difference between current and expected earnings. Its profitability remains strong, with a 57.2% gross margin, 15.65% operating margin, and 9.75% net margin. ROE is 9.14% and ROA is 4.90%.
Recent momentum. The latest quarter was uneven: Abbott reported $1.42 of EPS against a $1.43 estimate on October 21, 2026, a 0.7% miss. It has beaten estimates in three of the eight quarters shown, so recent execution is less consistent than CVS, BDX, or Medtronic. Still, the analyst panel contains five Buys and five Holds, with no Sell count provided; the consensus score is 4.4643 and the average target is $118.9073.
Pick #2Premium members only
Premium members see this pick's full breakdown — investment thesis, key financial metrics, recent earnings execution, and analyst consensus.
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
The monthly screen begins with US-listed healthcare companies above $500 million in market capitalization and favors businesses with substantial exposure to medicines, devices, diagnostics, distribution, pharmacy benefits, insurance, or related healthcare services. Candidates are ranked in countdown order first by the depth of that exposure, then by fundamentals such as revenue and earnings growth, margins, returns on capital, valuation, leverage signals, earnings consistency, and analyst sentiment. Composite quality grades summarize several of those measures. The universe and data are refreshed monthly, so valuation, consensus, earnings records, and company rankings may change in the next edition.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.